Home Pipeline

Overview

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.

 

Program (Target)
Indications
Pre-IND Phase 1 Phase 2 Phase 3 Collaborator Our Commercial Rights
Oncology
Margetuximab (HER2) Zai Lab, GC Pharma Worldwide, excluding South Korea and Greater China
Breast (HER2+) “SOPHIA”
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
placeholder
placeholder
placeholder
Enoblituzumab (B7–H3) I-Mab Biopharma Worldwide, excluding Greater China
Solid Tumors (+anti-PD-1)
placeholder
placeholder
placeholder
MGD009 (B7-H3 x CD3) Worldwide
Solid Tumors
placeholder
placeholder
Solid Tumors (+MGA012)
placeholder
placeholder
MGC018 (B7-H3)(a) Worldwide
Solid Tumors
placeholder
placeholder
MGA012 (PD-1) Incyte(b)
Solid Tumors
placeholder
placeholder
placeholder
MGD013 (PD-1 x LAG-3) Zai Lab Worldwide, excluding Greater China
Solid Tumors/Heme Mal.
placeholder
placeholder
MGD019 (PD-1 x CTLA-4) Worldwide
Solid Tumors
placeholder
placeholder
Flotetuzumab (CD123 x CD3) Worldwide
AML
placeholder
placeholder
AML (+MGA012)
placeholder
MGD007 (gpA33 x CD3) Worldwide
Colorectal (+MGA012)
placeholder
placeholder

Oncology
Breast (HER2+) “SOPHIA”
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
placeholder
Gastric (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
PartnerZai Lab, Green Cross
Our Commercial RightsWorldwide, excluding South Korea and Greater China
Solid Tumors (+anti-PD-1)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
PartnerI-Mab Biopharma
Our Commercial RightsWorldwide, excluding Greater China
MGD009 (B7-H3 x CD3)
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Solid Tumors (+MGA012)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
MGC018 (B7-H3)(a)
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide

MGA012 (PD-1)
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
placeholder
PartnerIncyte*
Our Commercial Rights
MGD013 (PD-1 x LAG-3)
Solid Tumors/Heme Mal.
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
PartnerZai Lab
Our Commercial RightsWorldwide, excluding Greater China
MGD019 (PD-1 x CTLA-4)
Solid Tumors
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Our Commercial RightsWorldwide
Flotetuzumab (CD123 x CD3)
AML
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
AML (+MGA012)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
PartnerServier
Our Commercial RightsNorth America, Japan, Korea, India
MGD007 (gpA33 x CD3)
Colorectal (+MGA012)
Pre-IND Phase 1 Phase 2 Phase 3
placeholder
placeholder
Partner
Our Commercial RightsWorldwide

“MGD” = DART “MGA” = Antibody“MGC” = ADC
(a) MGC018 is an antibody-drug conjugate (ADC) based on a duocarmycin payload with cleavable peptide linker that was licensed from Synthon Biopharmaceuticals.
(b) MacroGenics retains rights to develop its pipeline assets in combination w/MGA012 and to manufacture a portion of global clinical and commercial supply needs of MGA012. Incyte designates this molecule as “INCMGA0012”.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close